While the government contract to date has been pro forma–the University of Mississippi/Oxford has won the contract every year since the late 1960s and MAPS’ and Prof. Lyle Craker’s successful lawsuit against the Drug Enforcement Administration (DEA) to effectively break Ol’ Miss’ monopoly on cultivating cannabis for research and approximately five Compassionate IND patients, and allow the University of Massachusetts/Amherst to cultivate research and therapeutic grade cannabis, is being appealed by DEA–competition can only help science, and the free market place of ideas and research.
Production, Analysis, & Distribution of Cannabis & Marijuana Cigarettes
Solicitation Number: N01DA-10-7773
Agency: Department of Health and Human Services
Office: National Institutes of Health
Location: National Institute on Drug Abuse
Added: Aug 05, 2009 9:03 am
The National Institute on Drug Abuse is soliciting proposals from qualified organizations having the capability to (1) grow, harvest, analyze, store and distribute GMP grade cannabis (marijuana) on large and small scales; (2) extract cannabis to obtain purified phytocannabinoids including delta-9-tetrahydrocannabinol (delta-9-THC), analyze, and store; (3) prepare marijuana cigarettes and related products; and (4) distribute marijuana, marijuana cigarettes and cannabinoids, and other related products for research and other Government programs upon NIDA authorization.
Offerors must possess suitable and secure DEA approved outdoor and indoor growing facilities, research laboratory with appropriate analytical instruments, and experienced personnel to conduct the project tasks. Appropriate DEA approved secure facility for manufacturing of marijuana cigarettes, and their storage, and DEA Schedule I registration for marijuana and THC are essential. NIDA anticipates a 1-year with four 1 year options cost reimbursement type contract will be awarded. Additional quantity options for manufacturing cigarettes may also be required. In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. All studies must be carried out under pertinent FDA regulations, such as current Good Clinical Practice (cGCP) and current Good Laboratory Practice (cGLP) regulations. The pertinent FDA’s guidelines/guidance shall be followed. RFP No. N01DA-10-7773 will be available electronically on or about August 25, 2009. You can access the RFP through the FedBizOpps:
http://fbo.gov or through the NIDA website at the following address: http://www.nida.nih.gov/RFP/RFPList.html.
The electronic RFP contains all information needed to submit a proposal. No printed version of the solicitation document or source list is available. NIDA will consider proposals submitted by any responsible offeror. Proposals will be due on or about October 9, 2009. This advertisement does not commit the Government to award a contract. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government’s requirement with a commercial item within 15 days of this notice.
Contracting Office Address:
6101 Executive Boulevard
Room 260 – MSC 8402
Bethesda, Maryland 20892
Primary Point of Contact.: